Global Hepatitis Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Hepatitis Therapeutics Market was valued at $17.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.1% CAGR, to an estimated market size of $21.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global hepatitis therapeutics market encompasses pharmaceutical treatments, vaccines, and disease management solutions for viral hepatitis (A, B, C, D, and E). The scope includes direct-acting antivirals (DAAs), nucleos(t)ide analogs, immunomodulators, and emerging novel therapeutic modalities such as siRNAs and capsid assembly modulators, while excluding diagnostic hardware and general hospital services.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Hepatitis Therapeutics Market in the period 2025-30:
- The market is transitioning from suppressive regimens to functional-cure combinations that target viral replication and host-factor interactions.
- Widespread adoption of pan-genotypic DAAs has simplified treatment protocols by removing the need for genotype testing and improving patient adherence.
- National elimination programs and WHO 2030 goals are driving aggressive screening and treatment expansion in emerging economies.
- A depletion effect is observed in mature markets where high cure rates for Hepatitis C are shrinking the pool of chronically infected individuals.
- Value-based procurement models, such as pay-for-cure or subscription-style contracts, are being implemented to manage high therapy costs.
- AI-enabled drug discovery and predictive modeling are accelerating the development of novel therapeutic modalities like siRNAs and capsid assembly modulators.
- Significant underdiagnosis remains a major market barrier, with only a small fraction of the global infected population currently identified and treated.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Asia-Pacific
- Europe
- Rest of World
Segments
- Hepatitis C
- Hepatitis B
- Other Hepatitis (A, D, E)